190 related articles for article (PubMed ID: 23440732)
21. Meta-analysis demonstrates lack of association of the GSK3B -50C/T polymorphism with risk of bipolar disorder.
Chen G; Tang J; Yu G; Chen Y; Wang L; Zhang Y
Mol Biol Rep; 2014 Sep; 41(9):5711-8. PubMed ID: 24929537
[TBL] [Abstract][Full Text] [Related]
22. Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders.
Serretti A; Benedetti F; Mandelli L; Calati R; Caneva B; Lorenzi C; Fontana V; Colombo C; Smeraldi E
Psychiatry Res; 2008 Mar; 158(2):132-40. PubMed ID: 17976739
[TBL] [Abstract][Full Text] [Related]
23. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients.
Szczepankiewicz A; Rybakowski JK; Suwalska A; Skibinska M; Leszczynska-Rodziewicz A; Dmitrzak-Weglarz M; Czerski PM; Hauser J
World J Biol Psychiatry; 2006; 7(3):158-61. PubMed ID: 16861141
[TBL] [Abstract][Full Text] [Related]
24. Looking ahead: electroretinographic anomalies, glycogen synthase kinase-3, and biomarkers for neuropsychiatric disorders.
Chen G; Henter ID; Manji HK
Biol Psychiatry; 2014 Jul; 76(2):86-8. PubMed ID: 24948381
[No Abstract] [Full Text] [Related]
25. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.
Iwahashi K; Nishizawa D; Narita S; Numajiri M; Murayama O; Yoshihara E; Onozawa Y; Nagahori K; Fukamauchi F; Ikeda K; Ishigooka J
Clin Neuropharmacol; 2014; 37(4):108-10. PubMed ID: 24992082
[TBL] [Abstract][Full Text] [Related]
26. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
[TBL] [Abstract][Full Text] [Related]
27. Schizophrenia as a GSK-3 dysregulation disorder.
Lovestone S; Killick R; Di Forti M; Murray R
Trends Neurosci; 2007 Apr; 30(4):142-9. PubMed ID: 17324475
[TBL] [Abstract][Full Text] [Related]
28. Low GSK-3 activity in frontal cortex of schizophrenic patients.
Kozlovsky N; Belmaker RH; Agam G
Schizophr Res; 2001 Oct; 52(1-2):101-5. PubMed ID: 11595396
[TBL] [Abstract][Full Text] [Related]
29. Association analysis of the glycogen synthase kinase-3beta gene in bipolar disorder.
Nishiguchi N; Breen G; Russ C; St Clair D; Collier D
Neurosci Lett; 2006 Feb; 394(3):243-5. PubMed ID: 16289783
[TBL] [Abstract][Full Text] [Related]
30. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
31. GSK-3 parameters in lymphocytes of schizophrenic patients.
Nadri C; Kozlovsky N; Agam G; Bersudsky Y
Psychiatry Res; 2002 Sep; 112(1):51-7. PubMed ID: 12379450
[TBL] [Abstract][Full Text] [Related]
32. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.
Benedetti F; Serretti A; Pontiggia A; Bernasconi A; Lorenzi C; Colombo C; Smeraldi E
Neurosci Lett; 2005 Mar; 376(1):51-5. PubMed ID: 15694273
[TBL] [Abstract][Full Text] [Related]
33. Genetic variability at IMPA2, INPP1 and GSK3β increases the risk of suicidal behavior in bipolar patients.
Jiménez E; Arias B; Mitjans M; Goikolea JM; Roda E; Sáiz PA; García-Portilla MP; Burón P; Bobes J; Oquendo MA; Vieta E; Benabarre A
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1452-62. PubMed ID: 23453640
[TBL] [Abstract][Full Text] [Related]
34. GSK3B and schizophrenia: a case not closed.
Sand PG; Domani M; Smesny S
Psychopharmacology (Berl); 2010 Feb; 208(2):333-4; author reply 335-6. PubMed ID: 19936977
[No Abstract] [Full Text] [Related]
35. Association of a GSK-3β polymorphism with brain resting-state function in amnestic-type mild cognitive impairment.
Bai F; Shi Y; Yuan Y; Yue C; Zhuang L; Xu X; Liu X; Zhang Z
J Alzheimers Dis; 2012; 32(2):387-96. PubMed ID: 22785398
[TBL] [Abstract][Full Text] [Related]
36. The role of glycogen synthase kinase-3beta in schizophrenia.
Koros E; Dorner-Ciossek C
Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
[TBL] [Abstract][Full Text] [Related]
37. TRPM2, a Susceptibility Gene for Bipolar Disorder, Regulates Glycogen Synthase Kinase-3 Activity in the Brain.
Jang Y; Lee SH; Lee B; Jung S; Khalid A; Uchida K; Tominaga M; Jeon D; Oh U
J Neurosci; 2015 Aug; 35(34):11811-23. PubMed ID: 26311765
[TBL] [Abstract][Full Text] [Related]
38. Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia.
Scassellati C; Bonvicini C; Perez J; Bocchio-Chiavetto L; Tura GB; Rossi G; Racagni G; Gennarelli M
Neuropsychobiology; 2004; 50(1):16-20. PubMed ID: 15179015
[TBL] [Abstract][Full Text] [Related]
39. Association between GSK3β gene and increased impulsivity in bipolar disorder.
Jiménez E; Arias B; Mitjans M; Goikolea JM; Roda E; Ruíz V; Pérez A; Sáiz PA; García-Portilla MP; Burón P; Bobes J; Vieta E; Benabarre A
Eur Neuropsychopharmacol; 2014 Apr; 24(4):510-8. PubMed ID: 24486183
[TBL] [Abstract][Full Text] [Related]
40. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies.
Zintzaras E
Psychiatr Genet; 2006 Jun; 16(3):105-15. PubMed ID: 16691128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
